Compare USCB & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USCB | PROK |
|---|---|---|
| Founded | 2002 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 371.1M | 316.0M |
| IPO Year | 2021 | 2021 |
| Metric | USCB | PROK |
|---|---|---|
| Price | $23.12 | $1.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $23.00 | $7.40 |
| AVG Volume (30 Days) | 55.4K | ★ 1.1M |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 7.26 | N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $26.46 | N/A |
| Revenue Next Year | $9.67 | N/A |
| P/E Ratio | $22.87 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $16.36 | $1.30 |
| 52 Week High | $23.89 | $3.48 |
| Indicator | USCB | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 60.00 | 55.81 |
| Support Level | $21.92 | $1.73 |
| Resistance Level | $23.81 | $1.96 |
| Average True Range (ATR) | 0.58 | 0.12 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 57.66 | 61.36 |
USCB Financial Holdings Inc is a bank holding company. Through its banking subsidiary, it offers relationship-based banking products, services, and solutions to a diverse set of clients in the local markets it operates in and international clients with U.S. banking needs. The Group's products and services offerings mainly include traditional deposit products, including commercial and consumer checking accounts, money market deposit accounts, savings accounts, etc.; e-banking services; title insurance policies for real estate transactions; and a variety of lending products such as small business loans, commercial real estate loans, business credit cards, etc.; and others. Geographically, its primary banking market is South Florida.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.